FOLH1 and prostate cancer: While THPMe itself has not been evaluated in humans yet, one of its derivatives, THPMe-PSMA labelled with 68Ga, is in phase III clinical trials for imaging prostate cancer suggesting low toxicity of the THPMe family and potential for clinical translation.